ALTERITY THERAPEUTICS LIMITED (ATH)
Share Price Analysis and Chart

07/04/2026

1

Speculative Buy

$0.016

77.78%

Canaccord Genuity maintains a Speculative Buy rating and $0.016 target for Alterity Therapeutics following a positive FDA Type C meeting on safety and toxicology data for lead candidate ATH434, which the broker notes has meaningfully improved timeline visibility for the program.

Critical manufacturing scale-up and formal end of Phase II meetings are expected by mid-2026 to shape Phase III trial design.

First-half OpEx rose 50% to -$13.2m driven by higher share-based payments and general and administrative expenses, though the broker considers the impact on valuation negligible.

The analyst sees securing FDA agreement on a well-powered Phase III trial and potential partnering or licensing arrangements as the primary re-rating catalysts.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.20 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.30 cents.